u
r
reduct
durat
common
cold
shown
ebi
et
al
use
mg
zinc
glucon
throat
lozeng
follow
year
doubleblind
placebocontrol
random
clinic
trial
produc
wide
differ
result
onehalf
show
success
remaind
show
failur
posit
charg
ionic
zinc
izn
bound
zinc
strongli
astring
antirhinovir
increas
interferongamma
ifnc
inhibit
intercellular
adhes
inhibit
releas
vasoact
ingredi
mast
cell
granul
solut
equilibrium
chemistri
analyt
techniqu
show
lozeng
izn
fraction
vari
total
lozeng
zinc
trial
zinc
acet
za
releas
izn
zinc
glucon
zg
releas
izn
zinc
compound
releas
much
less
none
physiolog
ph
sinc
izn
vitro
benefit
izn
variat
hypothes
produc
wide
vari
clinic
result
support
izn
hypothesi
lozeng
izn
total
daili
izn
trial
found
highli
correl
reduct
common
cold
durat
statist
signific
mean
durat
p
median
durat
p
total
zinc
izn
plu
bound
show
correl
chang
durat
durat
reduct
mean
day
median
day
multiligand
zg
za
lozeng
differ
significantli
durat
reduct
mean
day
median
day
singl
ligand
za
zg
lozeng
p
show
addit
ligand
flavormask
damag
elimin
efficaci
five
trial
lozeng
whose
zinc
composit
first
stabil
constant
less
succeed
trial
lozeng
higher
stabil
succeed
p
strong
multipl
statist
relationship
found
infer
izn
activ
ingredi
zinc
lozeng
cold
vitro
rhinovirus
solut
chemistri
analyt
techniqu
use
physiolog
ph
correct
mean
lozeng
izn
analysi
zinc
lozeng
slowli
dissolv
mouth
min
period
releas
adequ
izn
mg
use
h
hypothes
shorten
common
cold
day
cure
common
cold
due
inadequ
lozeng
izn
differ
brand
zinc
lozeng
us
market
expect
effect
durat
sever
common
cold
viral
pathogen
primarili
associ
upper
respiratori
tract
infect
common
cold
includ
sever
hundr
picornavirus
notabl
rhinovirus
enterovirus
coronavirus
adenovirus
parainfluenza
virus
influenza
virus
respiratori
syncyti
virus
consequ
vaccinebas
cure
common
cold
hinder
larg
number
virus
caus
common
cold
noninfluenzarel
viral
respiratori
tract
infect
common
cold
frequent
reason
offic
visit
adult
children
gener
practic
physician
account
one
hundr
million
primari
care
visit
econom
impact
billion
per
year
unit
state
inappropri
prescript
antibiot
treat
viral
common
cold
occur
offic
visit
result
unnecessari
cost
contribut
antibiot
resist
exposur
sever
antibiot
side
effect
especi
fluoroquinolon
use
great
public
need
safe
effect
cure
common
cold
zinc
lozeng
hypothes
cure
common
cold
vitro
posit
charg
ioniz
zinc
izn
bound
zinc
demonstr
strong
antirhinovir
activ
inhibit
normal
cleavag
viral
polypeptid
process
ionic
zinc
inhibit
intercellular
adhes
ionic
zinc
increas
interferongamma
ifnc
ionic
zinc
inhibit
releas
histamin
leukotrien
basophil
mast
cell
protect
cellplasma
membran
includ
mast
goblet
cell
benefit
treat
allergi
ionic
zinc
also
antivir
effect
respiratori
virus
includ
herp
viru
respiratori
syncyti
viru
regardless
vitro
benefit
result
placebocontrol
doubleblind
random
clinic
trial
rct
zinc
lozeng
common
cold
conduct
rang
reduc
durat
cold
day
origin
ebi
et
al
rct
lengthen
cold
day
dougla
studi
relationship
total
zinc
lozeng
effect
durat
cold
unusu
unexpect
rang
respons
caus
therapeut
controversi
variat
clinic
result
hypothes
caus
variat
lozeng
izn
solut
equilibrium
chemistri
comput
field
inorgan
chemistri
hypothes
provid
scientif
valid
mean
determin
izn
avail
lozeng
variabl
comput
includ
metal
ligand
stabil
constant
ph
pk
valu
concentr
temperatur
absorpt
use
izn
throat
lozeng
local
oral
throat
nasal
tissu
consequ
ph
mean
treatment
cold
hypothes
physiolog
ph
comput
temperatur
held
constant
zinc
concentr
held
constant
mmol
izn
minor
variat
variabl
rang
use
rct
believ
relev
common
zinc
compound
releas
substanti
izn
physiolog
ph
zinc
chlorid
sulfat
acet
glucon
known
sourc
posit
charg
ionic
zinc
speci
alway
produc
characterist
metal
tast
dri
astring
mouthfeel
use
solut
chemistri
comput
foundat
fig
show
great
variabl
amount
izn
zinc
compound
ph
line
fig
percent
izn
sum
posit
charg
zinc
speci
ph
taken
detail
comput
perform
solut
chemist
specif
articl
zinc
lozeng
cold
cure
candi
solut
chemistri
determin
ph
remaind
zinc
total
zinc
minu
izn
bound
zinc
comput
util
us
depart
commerc
nation
institut
standard
technolog
nist
solut
equilibrium
inorgan
chemistri
data
base
comput
includ
interact
izn
protein
lipid
carbohydr
present
saliva
oral
nasal
tissu
although
interact
import
mainli
result
requir
much
larger
concentr
izn
would
requir
biolog
effect
vitro
fig
stomach
acid
ph
composit
releas
izn
nearli
zero
bound
zinc
saliva
measur
ph
zinc
composit
except
zinc
gluconatecitr
zgc
releas
larg
amount
izn
explain
commerci
zinc
lozeng
except
zgc
tast
astring
consequ
oral
astring
reliabl
indic
izn
physiolog
ph
zarembo
et
al
report
zinc
gluconateglycin
zgg
releas
izn
data
point
fig
measur
taken
salivari
ph
effect
second
ligand
glycin
weak
reduc
izn
physiolog
ph
glycin
action
much
stronger
ph
zinc
acet
za
releas
izn
first
stabil
constant
k
logarithm
zinc
acet
equal
mean
zinc
total
ionic
solut
ph
shown
k
zinc
glucon
equal
zinc
slightli
less
ionic
zinc
acet
solut
k
zinc
tartrat
equal
yield
amount
ionic
zinc
found
zinc
acet
k
zinc
glycin
zinc
citrat
equal
yield
much
less
zinc
composit
shown
ionic
zinc
respect
physiolog
ph
k
zinc
aspart
equal
time
tightli
bound
zinc
acet
yield
ionic
zinc
physiolog
ph
zinc
composit
low
chemic
stabil
releas
much
izn
littl
bound
zinc
physiolog
ph
higher
stabil
releas
mainli
bound
zinc
unstabl
zinc
compound
react
ingredi
lozeng
situ
saliva
produc
reaction
product
vastli
differ
chemic
properti
includ
elimin
izn
multipl
hypothes
test
analysi
hypothesi
solut
equilibrium
chemistri
appropri
mean
determin
amount
izn
physiolog
ph
oral
nasal
tissu
blood
suggest
valid
izn
doserespons
statist
relationship
found
strong
hypothesi
relev
ph
physiolog
ph
support
countless
data
show
tissu
oral
nasal
tissu
blood
normal
physiolog
ph
ph
import
analysi
sinc
amount
izn
vari
greatli
ph
well
zinc
composit
research
advoc
relev
ph
ph
salivari
ph
reanalysi
amount
izn
found
trial
ph
show
godfrey
et
al
zgg
trial
impact
strongli
shift
rhinovirus
believ
infect
nasal
adenoid
cell
saliva
oral
cell
consequ
physiolog
ph
hypothes
correct
ph
make
izn
observ
search
evid
zinc
lozeng
cure
common
cold
review
consid
englishlanguag
report
concern
zinc
lozeng
cold
index
pubm
januari
septemb
search
consist
zinc
common
cold
articl
zinc
common
cold
articl
rct
publish
previous
book
vitro
report
zinc
rhinovirus
articl
also
review
zinc
common
cold
rct
exclud
result
thorough
review
literatur
fifteen
rct
found
analyz
solut
equilibrium
chemistri
data
clinic
result
rct
critic
solut
equilibrium
chemistri
inform
necessari
determin
amount
activ
ingredi
izn
omit
origin
articl
found
support
literatur
mainli
concern
unreport
addit
foodacid
flavormask
elimin
metal
tast
astring
mouthfeel
izn
identif
zinc
compound
releas
izn
applic
fraction
amount
zinc
izn
shown
fig
amount
izn
trial
statist
show
strong
relationship
izn
effect
durat
cold
ebi
et
al
first
report
zinc
glucon
zg
lozeng
patient
rct
effect
treatment
common
cold
one
zinc
mg
izn
lozeng
calcium
lactat
placebo
dissolv
mouth
everi
wake
hour
initi
doubl
dose
dose
per
day
first
day
load
dose
dose
day
treatment
zinctreat
subject
asymptomat
compar
placebotr
subject
p
produc
statist
signific
meaning
benefit
zinc
lozeng
shorten
median
durat
cold
day
mean
durat
day
patient
group
ill
averag
day
prior
admiss
group
well
balanc
patient
characterist
dropout
return
report
hypothet
consid
neg
respond
posit
result
remain
statist
sound
p
zg
lozeng
unflavor
compress
tablet
dissolv
min
mouth
contain
mg
zinc
activ
ingredi
mg
calcium
lactat
inact
ingredi
tablet
otherwis
ident
includ
excipi
dicalcium
phosphat
microcrystallin
cellulos
sodium
starch
glycol
magnesium
stearat
fd
c
yellow
blue
aluminum
lake
lozeng
chalki
nonbitt
tast
strongli
dri
astring
alnakib
et
al
british
medic
research
council
common
cold
unit
ccu
salisburi
england
use
zg
lozeng
contain
mg
zinc
mg
izn
use
time
per
day
treat
rhinovirusinduc
cold
patient
rct
lozeng
dissolv
mouth
min
zinc
reduc
daili
mean
clinic
score
sever
averag
number
symptom
placebotr
group
zinctreat
group
reduct
statist
signific
second
day
viru
challeng
p
total
mean
clinic
score
sum
mean
clinic
score
day
reduc
placebotr
group
zinctreat
group
p
object
score
includ
mean
nasal
secret
weight
p
total
tissu
count
p
also
significantli
reduc
zinc
group
compar
placebo
strongli
anisett
flavor
wet
granul
compress
lozeng
design
rinaldo
pellegrini
md
phd
rb
pharmamilan
milano
itali
fructos
methylcellulos
tablet
base
magnesium
stearat
lubric
produc
strongli
dri
astring
mouthfeel
nonbitt
pleasant
tast
zg
lozeng
estim
shorten
mean
durat
cold
day
compar
match
placebo
alnakib
et
al
articl
review
extend
book
includ
estim
reduct
durat
data
full
cooper
ccu
personnel
also
wrote
foreword
fructos
carbohydr
sweeten
becom
bitter
age
sever
week
combin
zinc
glucon
accompani
prophylaxi
studi
alnakib
et
al
total
volunt
receiv
lozeng
either
zg
mg
zinc
match
placebo
everi
h
awak
period
four
half
day
challeng
tissu
cultur
infect
dose
human
rhinoviru
second
day
medic
zinc
placebo
monitor
daili
symptom
sign
develop
cold
laboratori
evid
infect
treatment
prophylact
trial
show
respons
zinctreat
statist
signific
first
day
viral
challeng
zinc
reduc
total
clinic
score
compar
placebo
vs
mean
nasal
secret
weight
viru
excret
even
though
treatment
stop
third
day
viral
challeng
mean
clinic
score
zinctreat
group
fourth
fifth
sixth
day
remain
lower
placebotr
group
day
four
day
five
sixth
day
studi
produc
meaning
statist
signific
posit
result
histori
ccu
unpublish
trial
mccutcheon
et
al
describ
letter
use
mg
zinc
zinc
aspart
zp
nine
time
daili
first
trial
use
nonioniz
zinc
mg
izn
trial
compris
univers
student
common
cold
symptom
day
less
enrol
studi
metal
tast
astring
reduct
durat
cold
berthon
germonneau
demonstr
izn
essenti
unavail
total
bound
zinc
aspart
physiolog
ph
g
sucros
fructos
lozeng
also
contain
calcium
ascorb
bee
propoli
slipperi
elm
vitamin
palmit
sugar
stearat
duratex
tm
spraydri
flavor
oil
zinc
aspart
placebo
lozeng
first
rct
zinc
lozeng
cold
mention
addit
foodacid
flavor
mask
report
farr
et
al
univers
virginia
studi
patient
use
hardboil
g
sugar
corn
syrup
lozeng
contain
mg
zinc
glucon
mg
citric
acid
lozeng
weight
lemon
flavor
lozeng
match
placebo
given
eight
time
daili
treat
laboratoryinduc
cold
signific
ad
citric
acid
unknown
articl
solut
chemist
r
bruce
martin
phd
publish
show
absenc
ionic
zinc
presenc
neg
charg
zinc
speci
physiolog
ph
lozeng
pleasant
tast
nonastring
nondri
nonmetal
flavor
essenti
indistinguish
placebo
reaction
product
tightli
bound
zinc
citrat
mg
izn
activ
lozeng
appear
lengthen
mean
durat
cold
least
one
day
compar
placebo
sinc
tissu
usag
higher
activ
group
placebo
group
day
trial
formul
common
zinc
lozeng
formul
unit
state
market
result
zinc
lozeng
shorten
common
cold
dougla
et
al
rct
report
omit
mention
addit
food
acid
effervesc
zinc
acet
lozeng
use
treat
natur
cold
subject
adelaid
south
australia
averag
durat
zinctreat
group
day
versu
averag
day
placebotr
group
cold
durat
increas
day
strongli
effervesc
zinc
acet
za
zinc
lozeng
use
time
daili
compar
placebo
letter
lozeng
design
manufactur
fauld
ltd
adelaid
south
australia
indic
lozeng
contain
zinc
acet
plu
tartar
acid
sodium
bicarbon
zatb
suffici
result
strong
oral
effervesc
zinc
acet
dissoci
presenc
ad
ingredi
form
sever
tightli
bound
reaction
product
includ
zinc
carbon
nonsolubl
nonioniz
neg
charg
zinc
tartrat
speci
mg
izn
zinc
lozeng
appear
releas
suffici
neg
charg
zinc
speci
neutral
nativ
izn
mast
cell
granul
infect
nasal
epithelium
result
significantli
worsen
cold
symptom
glucon
bind
izn
time
less
strongli
tartrat
minor
ingredi
includ
talc
magnesium
stearat
lubric
color
flavor
smith
et
al
report
zg
lozeng
mg
zinc
lozeng
mg
izn
total
use
nine
time
per
day
patient
natur
cold
lozeng
reduc
symptom
sever
compar
placebo
day
p
effect
durat
cold
lozeng
also
contain
sucros
fructos
sorbitol
mannitol
miner
acid
stearat
methocel
pineappl
powder
three
spraydri
flavor
zinc
placebo
lozeng
clinic
trial
trial
review
consid
outlier
statu
result
extrem
bitter
equival
ultrabitt
placebo
contain
sucros
octaacet
prevent
patient
use
lozeng
expector
nonus
lozeng
common
person
commun
cb
goswick
weisman
et
al
studi
zg
lozeng
given
time
per
day
rct
subject
copenhagen
denmark
treat
natur
cold
found
statist
signific
effect
lozeng
cold
durat
lozeng
contain
mg
zinc
mg
izn
flavor
hardboil
maltitolsyrup
candi
highest
concentr
zinc
possibl
candi
base
without
extrem
bitter
maltitol
liquid
food
ingredi
consist
dri
substanc
contain
hydrogen
disaccharid
maximum
dsorbitol
approxim
hydrogen
disaccharid
degre
polymer
higher
two
godfrey
et
al
studi
zinc
gluconateglycin
zgg
lozeng
contain
mg
zinc
mol
zinc
glucon
mol
glycin
g
orangeflavor
hard
boil
sucros
corn
syrup
lozeng
rct
lozeng
use
averag
time
per
day
studi
involv
patient
treatment
natur
cold
zinctreat
cold
last
averag
day
compar
placebotr
cold
day
shorten
day
compar
placebo
p
reaction
product
mostli
bound
zinc
glycin
mg
izn
assert
reduct
durat
cold
support
placebocontrol
data
rct
involv
subject
mossad
et
al
mg
zinc
zgg
lozeng
ratio
zinc
glucon
glycin
use
six
time
daili
meaning
reduc
median
cold
durat
day
day
zinctreat
vs
day
placebotreat
p
reduc
mean
durat
day
day
zinctreat
vs
day
placebotreat
p
g
hard
boil
candi
lozeng
also
contain
sucros
corn
syrup
lemon
lime
flavor
oil
reaction
product
onehalf
zinc
glycin
mg
izn
macknin
et
al
rct
children
found
zgg
lozeng
mg
zinc
use
six
time
daili
affect
durat
children
cold
g
hard
boil
candi
lozeng
also
contain
sucros
corn
syrup
cherryflavor
oil
time
symptom
resolut
day
group
daili
resolut
rate
cold
symptom
appear
ident
group
plot
graph
differ
day
absent
school
found
reaction
product
onehalf
zinc
glycin
mg
izn
petru
et
al
use
zinc
acet
za
lozeng
found
signific
reduct
mean
durat
day
zinc
day
placebo
day
differ
p
reduct
sever
common
cold
use
mg
zinc
mg
izn
lozeng
patient
lozeng
small
zinc
acet
lozeng
consist
dextros
tablet
base
glycerol
monostear
lubric
stevia
peppermint
oil
silica
gel
compress
forc
suffici
allow
dissolv
min
human
mouth
lozeng
use
h
first
day
everi
h
follow
day
wake
hour
lozeng
per
day
lozeng
meaning
reliev
cold
symptom
faster
patient
histori
allergi
without
activ
allergi
symptom
n
compar
allergyneg
subject
n
day
vs
day
p
prasad
et
al
found
signific
meaning
efficaci
use
mg
zinc
mg
izn
compress
za
lozeng
treat
natur
cold
patient
lozeng
use
h
per
day
fifti
percent
zinc
recipi
well
day
placebo
recipi
well
day
day
median
differ
zinc
group
also
shorter
mean
durat
cold
vs
day
p
day
mean
reduct
decreas
total
sever
score
symptom
p
good
placebo
blind
mild
side
effect
littl
differ
side
effect
compar
mild
tast
placebo
effect
suffici
strong
suggest
see
physician
bacteri
infect
symptom
significantli
improv
use
za
lozeng
day
zinc
acet
lozeng
peppermintflavor
consist
agglomer
dextros
tablet
base
glycerol
monostear
lubric
stevia
peppermint
oil
silica
gel
compress
forc
suffici
allow
dissolv
min
mouth
turner
cetnarowski
test
zgg
za
lozeng
use
natur
cold
induc
rhinoviru
cold
placebo
rct
lozeng
use
six
time
daili
given
patient
symptomat
zinc
zgg
lozeng
mg
izn
lengthen
median
durat
natur
cold
n
half
day
shorten
median
durat
human
rhinoviru
hrv
cold
n
one
day
compar
placebo
describ
ident
zgg
lozeng
test
previous
mossad
et
al
za
lozeng
lengthen
median
durat
natur
cold
n
half
day
effect
induc
cold
n
compar
placebo
za
lozeng
mg
zinc
effect
median
durat
natur
cold
n
shorten
cold
n
day
compar
placebo
hard
boil
za
lozeng
contain
sucros
glucos
syrup
artifici
flavor
citru
artifici
color
hydrogen
palm
kernel
oil
cotton
seed
oil
soy
lecithin
highli
acid
panoden
tm
surfact
high
cook
temperatur
use
ad
ingredi
react
ionic
za
produc
reaction
product
zinc
stearat
zinc
oleat
zinc
palmit
wax
zasop
nonsolubl
total
bound
mg
izn
incap
releas
izn
zinc
compound
found
fat
solubl
nonmisc
nonion
nonastring
hydrophob
lozeng
patent
us
patent
number
produc
substanti
reduct
unpleas
organolept
sensat
associ
releas
function
ingredi
confect
oral
caviti
ebi
halcomb
report
zinc
orot
zo
lozeng
mg
zinc
use
time
daili
along
mm
zinc
glucon
salin
nasal
spray
use
min
effect
cold
durat
person
rct
zinc
orot
tightli
bound
mg
izn
essenti
insolubl
nonsolubl
compound
releas
izn
g
lozeng
also
contain
gum
guar
cellulos
silica
veget
stearin
lozeng
nearli
insolubl
requir
h
dissolv
mouth
studi
second
compon
clinic
trial
result
publish
book
publish
peer
review
articl
prasad
et
al
rct
patient
use
za
hard
boil
candi
lozeng
contain
mg
zinc
mg
izn
lozeng
given
time
per
day
mean
reduct
cold
durat
day
patient
vs
day
p
day
subgroup
blind
patient
vs
day
p
sever
symptom
day
studi
meaning
significantli
reduc
zinctreat
group
p
hard
boil
lozeng
also
contain
sucros
corn
syrup
cherri
oil
prepar
use
open
pot
batch
method
activ
ingredi
anhydr
zinc
acet
ad
last
blind
adequ
advers
effect
group
differ
significantli
activ
monocyt
macrophag
decreas
izn
like
due
antioxid
effect
izn
intercellular
adhes
significantli
decreas
izn
compar
placebo
p
probabl
due
decreas
nuclear
factorkappab
nfjb
activ
suggest
decreas
plasma
level
due
izn
therapi
decreas
dock
cold
virus
surfac
somat
cell
human
rhinovirus
must
dock
surfac
somat
cell
produc
infect
thu
izn
act
antirhinovir
agent
reduc
well
directli
antivir
rhinovirus
increas
interferongamma
result
rct
organ
tabl
present
fig
b
test
hypothesi
izn
lozeng
might
cure
common
cold
total
daili
zinc
izn
plu
bound
zinc
intak
hypothes
relationship
efficaci
determin
zinc
lozeng
could
cure
common
cold
doubleblind
placebocontrol
data
doubleblind
placebocontrol
clinic
trial
use
determin
relationship
izn
zinc
reduct
durat
cold
test
correl
statist
signific
test
util
pearson
correl
weight
sampl
size
analysi
use
data
tabl
determin
statist
result
compil
tabl
lozeng
izn
content
correl
strongli
reduct
common
cold
durat
strong
statist
signific
meaning
differ
mean
durat
r
p
median
durat
r
p
without
smith
et
al
outlier
result
smith
et
al
outlier
also
statist
signific
total
daili
lozeng
izn
statist
also
strong
essenti
ident
lozeng
izn
statist
without
smith
et
al
outlier
relat
fig
b
nearli
zinc
lozeng
cure
common
cold
potenti
seen
one
ligand
acet
glucon
consequ
high
izn
content
fail
lozeng
multipl
ligand
consequ
low
null
izn
content
averag
mean
durat
reduct
day
multiligand
zg
za
lozeng
differ
significantli
averag
mean
durat
reduct
day
singl
ligand
za
zg
lozeng
p
similarli
averag
day
vs
day
median
durat
p
exclud
smith
et
al
outlier
tabl
statist
signific
differ
observ
total
zinc
izn
plu
bound
reduct
durat
either
mean
median
durat
without
smith
et
al
outlier
neg
result
search
cure
common
cold
also
typic
result
review
other
use
headcount
system
wherein
total
number
neg
zinc
cold
report
mean
median
compar
total
number
posit
report
mean
median
scientif
incorrect
mean
evalu
data
without
solut
chemistri
comput
determin
amount
izn
lozeng
neg
view
domin
view
zinc
lozeng
common
cold
research
report
use
multiligand
nonioniz
zinc
along
one
report
lozeng
low
amount
zinc
ultrabitt
smith
et
al
outlier
account
instanc
poor
null
lozeng
perform
tabl
five
six
formul
zinc
compound
first
stabil
constant
k
less
succeed
formul
zinc
reaction
product
higher
k
valu
lack
solubl
succeed
p
consist
vitro
observ
antirhinovir
activ
izn
spss
version
use
calcul
weight
pearson
correl
signific
valu
associ
correl
calcul
r
p
calcul
found
http
wwwfacultyvassaredulowrytabshtml
r
weight
correl
tabl
effect
zinc
median
mean
durat
common
cold
coeffici
testspecif
sampl
size
enter
calcul
determin
signific
level
weight
correl
coeffici
given
sampl
size
statist
signific
correl
declar
twosid
p
valu
indic
cure
common
cold
hypothesi
posit
correl
lozeng
izn
content
lozeng
izn
total
daili
izn
reduct
durat
common
cold
confirm
multipl
measur
strong
statist
signific
meaning
equal
import
hypothesi
correl
total
izn
plu
bound
lozeng
zinc
cure
common
cold
also
confirm
hypothesi
solut
chemistri
analysi
physiolog
ph
appropri
mean
analysi
verifi
implic
highli
signific
doserespons
statist
result
obtain
although
strong
izn
lozeng
cure
common
cold
differ
formul
produc
differ
result
shorten
cold
suffici
consid
viabl
cure
common
cold
ioniz
zinc
izn
activ
ingredi
zinc
lozeng
consider
vital
accur
review
interpret
clinic
trial
zinc
lozeng
shorten
cold
doser
tabl
statist
relationship
sever
measur
lozeng
zinc
durat
common
cold
util
pearson
correl
weight
sampl
size
analysi
statist
without
smith
et
al
outlier
statist
smith
et
al
outlier
spons
manner
activ
ingredi
izn
measur
physiolog
ph
consid
result
statist
signific
highli
meaning
multipl
measur
indic
cure
common
cold
strong
lozeng
clinic
trial
high
izn
zinc
acet
lozeng
need
confirm
extend
observ
due
seriou
tast
issu
zinc
glucon
poor
choic
treat
cold
zinc
glucon
form
extrem
bitter
complex
sweet
carbohydr
except
fructos
result
bitternessinduc
noncompli
failur
sever
zinc
glucon
lozeng
trial
especi
smith
et
al
outlier
overrid
sourc
failur
requir
pharmaceut
market
compani
pleasant
tast
candylik
nonmetal
nonastring
nondri
zinc
lozeng
coupl
tast
requir
exact
placebomatch
requir
result
test
multiligand
nonion
zinc
composit
produc
nearli
clinic
failur
clinic
test
multiligand
zinc
lozeng
composit
strongli
discourag
failur
could
attribut
infrequ
treatment
rapid
dissolut
lozeng
sinc
time
contact
requir
fick
second
law
membran
diffus
exampl
author
preclin
research
earli
highli
effect
zinc
glucon
lozeng
use
clinic
trial
appear
effect
given
interv
sinc
rhinovir
replic
extrem
rapid
infrequ
administr
izn
result
loss
control
viral
replic
produc
clinic
failur
reduct
benefit
take
effect
zinc
lozeng
less
frequent
h
appar
patient
zinc
lozeng
use
futur
clinic
trial
dissolv
mouth
min
sooner
best
efficaci
success
zinc
lozeng
other
hypothes
intranas
izn
cold
would
effect
perhap
superior
found
administr
mm
zinc
glucon
antirhinovir
concentr
nasal
spray
min
ineffect
shorten
cold
even
though
preclin
observ
show
improv
symptom
intranas
izn
treatment
known
caus
persist
perman
anosmia
upon
contact
olfactori
bulb
sinc
use
therefor
suggest
uneth
unit
state
food
drug
administr
requir
discontinu
zinc
glucon
nasal
gel
common
cold
due
anosmia
risk
clinician
would
reason
hypothes
applic
izn
nose
would
prefer
throat
lozeng
sinc
rhinovirus
infect
nose
mouth
consider
biophys
mouthnos
biolog
close
electr
circuit
bcec
teach
differ
view
interior
nose
posit
charg
electr
rel
mouth
mv
nose
repel
posit
charg
substanc
includ
ionic
zinc
nasal
applic
circuit
addit
mani
bcec
describ
member
chairman
nobel
assembl
stockholm
sweden
mouthnos
potenti
differ
intranas
appli
izn
would
like
shown
effect
treat
common
cold
earli
intranas
ioniz
zinc
sulphocarbol
report
treatment
nasal
catarrh
franklin
shield
revers
field
use
intranas
zinc
ioniz
ionic
zinc
driven
appli
electr
voltag
prevent
allergi
common
cold
year
two
zinc
ioniz
offic
treatment
wenner
alexand
show
nasal
mucos
tissu
temporarili
damag
zinc
ioniz
treat
nose
izn
cold
presenc
mouthnos
electr
flux
analog
board
move
train
destin
electr
resist
interior
mouth
nose
rang
kx
low
resist
associ
frequent
cold
nasal
allergi
high
resist
associ
immun
respiratori
virus
lack
allergi
subject
highest
mouthnos
electr
resist
suggest
ident
popul
develop
common
cold
infect
rhinoviru
ionic
zinc
migrat
mouth
nose
zinc
lozeng
document
although
magnesium
throat
lozeng
appear
effect
rescu
treatment
adult
allergyinduc
asthma
greatli
worsen
lengthen
common
cold
chronic
sinus
increas
rhinovir
releas
exponenti
grow
candida
albi
can
doubl
herp
simplex
growth
geist
et
al
univers
virginia
school
medicin
conduct
vitro
antirhinovir
test
number
ionic
zinc
compound
studi
antirhinovir
effect
izn
overwhelm
presenc
cultur
medium
mmol
magnesium
chlorid
time
physiolog
concentr
exact
concentr
shown
year
previous
optim
effect
increas
rhinovir
cellular
releas
nine
antirhinoviru
test
ionic
zinc
compound
includ
superphysiolog
magnesium
show
strong
antirhinoviru
effect
inclus
magnesium
zinc
lozeng
placebo
common
cold
would
expect
base
upon
greatli
worsen
common
cold
worsen
chronic
rhinosinus
worsen
herp
simplexinduc
common
cold
hypothet
throat
lozeng
contain
ioniz
magnesium
might
caus
sever
sequela
includ
fatal
rhinovirusinduc
asthma
especi
children
swallow
magnesium
dietari
supplement
would
caus
side
effect
sinc
would
increas
intranas
intralung
magnesium
concentr
beyond
normal
physiolog
level
zinc
lozeng
shortterm
use
without
magnesium
believ
harmless
side
effect
alway
minor
includ
tast
disturb
zinc
glucon
mainli
less
frequent
nausea
vomit
dyspepsia
diarrhea
rare
occas
elderli
patient
experienc
noisom
bitter
tast
suggest
agerel
zinc
metabol
disord
larg
amount
zinc
ingest
month
induc
copper
defici
consequ
immun
suppress
possibl
neurolog
disord
zinc
acet
use
longterm
treatment
wilson
diseas
ioniz
zinc
compound
poorli
absorb
gastrointestin
tract
compar
zinc
picolin
izn
activ
ingredi
criteria
success
present
herein
appear
immeasur
import
superfici
criteria
use
caruso
et
al
claim
without
statist
evid
therapeut
effect
zinc
lozeng
yet
establish
reach
neg
conclus
efficaci
zinc
lozeng
natur
acquir
cold
ignor
izn
activ
ingredi
doserespons
criteria
omit
highli
authorit
british
medic
research
council
common
cold
unit
posit
trial
zg
lozeng
induc
cold
includ
neg
report
farr
et
al
zgc
lozeng
induc
cold
demonstr
cherri
pick
critic
posit
report
failur
meet
intent
treat
analysi
yet
discuss
show
dropout
return
report
hypothet
consid
neg
respond
posit
result
remain
statist
sound
p
also
critic
report
fail
show
similar
group
trial
onset
ignor
tabl
characterist
studi
group
show
success
random
critic
zinc
lozeng
common
cold
trial
demonstr
mechan
action
mandatori
intercellular
adhes
inhibit
function
prior
public
prasad
et
al
data
show
inhibit
izn
consid
biophys
properti
nose
mouth
reli
upon
faulti
geist
et
al
neg
vitro
assess
antivir
effect
izn
ignor
posit
report
dupont
pharmaceut
team
led
bruce
korant
phd
exhaust
studi
strong
antivir
effect
izn
nearli
rhinovirus
confirm
report
merluzzi
et
al
reject
conclus
posit
report
hypothesi
fail
disclos
conflictofinterest
patent
one
coauthor
jack
merritt
gwaltney
jr
md
zinc
nasal
spray
cold
us
patent
number
zinc
glucon
zincum
gluconicum
zinc
acet
zincum
aceticum
list
homoeopath
pharmacopoeia
unit
state
consequ
us
food
drug
administr
new
drug
applic
requir
zinc
lozeng
common
cold
drug
appropri
homeopath
label
appropri
effect
pleasant
tast
homeopath
formul
includ
zincum
aceticum
base
consist
agglomer
dextros
directli
compress
fructos
glycerol
monostear
lubric
flavor
oil
plate
onto
silica
gel
use
compress
tablet
ton
compress
forc
zincum
aceticum
ad
late
sucros
corn
syrup
hard
boil
candi
flavor
oil
fructos
sucros
dextros
corn
syrup
nonsolubl
ingredi
normal
react
zinc
acet
addit
ingredi
advis
mani
fat
react
advers
zinc
acet
elev
temperatur
elimin
izn
use
mean
durat
trend
line
fig
homeopath
formul
last
min
mouth
use
two
wake
hour
first
sever
day
need
afterward
result
follow
expect
reduct
mean
durat
cold
use
zincum
aceticum
lozeng
g
lozeng
mg
izn
day
reduct
g
lozeng
mg
izn
day
reduct
g
lozeng
mg
izn
day
reduct
g
lozeng
mg
izn
day
reduct
g
lozeng
mg
izn
day
reduct
analysi
lozeng
highest
izn
content
mg
izn
reason
consid
cure
common
cold
smaller
lozeng
consid
use
shorten
durat
cold
lozeng
adulter
alway
produc
strongli
astring
dri
mouthfeel
sweet
pleasant
tast
twentyf
year
initi
discoveri
ebi
concept
zinc
lozeng
cure
common
cold
remain
hypothesi
lack
understand
physiolog
mechan
mani
effect
therapi
american
physician
especi
nutrientbas
therapi
caus
reject
discoveri
like
previou
reject
medic
discoveri
call
tomato
effect
notion
refer
erron
fear
toxic
tomato
american
physician
centuri
sinc
plant
nightshad
famili
highli
toxic
even
though
european
commonli
ate
tomato
time
american
medic
expert
long
histori
resist
scientif
innov
defin
outsid
refer
nonphysician
research
increas
econom
medic
necess
viabl
common
cold
treatment
outweigh
emot
respons
discoveri
even
though
medic
doctor
taught
least
one
hundr
year
cure
common
cold
strong
izn
lozeng
hypothes
cure
common
cold
lack
regulatori
review
use
homeopath
law
dietari
supplement
regul
unit
state
even
though
throat
lozeng
allow
unit
state
dietari
supplement
health
educ
act
result
commerci
zinc
lozeng
poorli
effect
noneffect
addit
magnesium
lozeng
might
substanti
worsen
cold
ad
credenc
notion
zinc
lozeng
cure
cold
coldseason
market
survey
author
zinc
lozeng
found
nation
chain
store
austin
texa
usa
show
none
met
criteria
high
izn
content
long
dissolut
time
nearli
releas
zero
izn
zinc
lozeng
contain
zgg
analysi
slightli
shorten
cold
averag
day
mean
reduct
main
benefit
hypothes
strong
antihistamin
action
would
rapidli
increas
feel
wellb
zinc
lozeng
also
contain
citric
acid
slightli
worsen
cold
averag
day
mean
increas
zinc
lozeng
contain
nonioniz
ph
zinc
compound
includ
zinc
oxid
aspart
tartrat
picolin
orot
variou
amino
acid
chelat
believ
inefficaci
cold
choic
zinc
compound
releas
izn
ph
believ
predic
commerci
desir
avoid
oral
astring
dri
natur
izn
thu
cure
common
cold
preclud
market
forc
scienc
current
assess
overthecount
zinc
lozeng
maintain
internet
zinc
lozeng
market
unit
state
appear
compet
base
upon
tast
rather
efficaci
strong
izn
bound
zinc
aqueou
solut
strong
astring
low
cell
penetr
action
essenti
limit
cell
surfac
interstiti
space
permeabl
cell
membran
reduc
izn
cell
remain
viabl
ioniz
zinc
harden
cement
substanc
capillari
epithelium
inhibit
patholog
transcapillari
movement
plasma
protein
reduc
local
edema
inflamm
exud
addit
izn
reduc
mucu
secret
tissu
contain
goblet
cell
secretori
cell
caus
affect
area
becom
drier
heal
faster
strong
izn
lozeng
immedi
benefici
effect
excess
mucu
product
throat
congest
nasal
drainag
due
allergi
usual
dosag
suggest
one
two
mg
izn
lozeng
per
day
treatment
allergi
benefit
result
strong
astring
action
superphysiolog
izn
cell
membran
especi
mast
cell
basophil
cellplasma
membran
result
temporari
inhibit
cellular
mast
cell
granul
deriv
vasoact
agent
includ
histamin
prostaglandin
leukotrien
serotonin
bradykinin
cytokin
although
common
cold
symptom
caus
virus
bradykinin
cytokin
allergi
symptom
caus
allergen
histamin
leukotrien
concentr
izn
benefici
treat
condit
strong
natur
multipl
antiinflammatori
effect
help
explain
izn
benefici
treat
allergi
asthma
anaphylaxi
bronchiti
croup
zinc
also
mandatori
tcell
lymphocyt
cell
mediat
immun
give
support
role
treat
viral
infect
gener
rct
strong
direct
relationship
lozeng
izn
content
efficaci
evinc
cure
common
cold
highest
izn
content
activ
ingredi
zinc
lozeng
found
izn
total
zinc
izn
plu
bound
zinc
relat
efficaci
zinc
lozeng
slowli
dissolv
mouth
min
period
releas
adequ
izn
mg
use
h
shorten
common
cold
day
cure
common
cold
literatur
review
zinc
lozeng
rct
fulli
consid
solut
equilibrium
chemistri
izn
content
zinc
lozeng
appear
scientif
invalid
vitro
assess
antirhinovir
effect
zinc
compound
includ
unexplain
superphysiolog
magnesium
chlorid
growth
medium
appear
best
excess
stringent
test
worst
purpos
sabotag
test
zinc
lozeng
must
contain
ioniz
magnesium
sinc
expect
greatli
worsen
cold
exacerb
asthma
perhap
fatal
differ
brand
overthecount
zinc
lozeng
mani
variat
current
avail
us
base
upon
analysi
ingredi
list
label
appear
releas
use
amount
izn
regardless
total
zinc
content
none
consid
cure
common
cold
sever
except
nearli
appear
like
null
effect
cold
consist
notion
cure
common
cold
exceedingli
rare
highli
astring
dri
zinc
acet
lozeng
mg
izn
describ
herein
use
two
wake
hour
recommend
safe
effect
common
cold
cure
addit
highdosag
zinc
acet
lozeng
common
cold
research
need
confirm
extend
find
author
expir
patent
concern
zinc
lozeng
common
cold
exampl
us
patent
cure
common
cold
profit
patent
royalti
sale
http
wwwcoldcurecom
